A bioassay of the experimental anticancer drug @entity10976 for possible carcinogenicity was conducted by administering the compound by intraperitoneal injection to @entity35 and B6C3F1 @entity19 . Groups of 35 @entity35 and 35 @entity19 were injected three times per week with @entity10976 in buffered saline at one of the following doses, either 48 or 96 mg/kg body weight for the @entity35 and either 40 or 80 mg/kg body weight for the @entity19 . Both @entity35 and @entity19 were dosed for 52 weeks, then observed for 29-34 additional weeks. Untreated-control and vehicle-control groups each consisted of 10 @entity35 and 15 @entity19 of each sex; pooled-control groups consisted of the 10 vehicle controls of each sex of the @entity35 combined with 30 vehicle controls of each sex of @entity35 from similar bioassays of three other chemicals and the 15 vehicle controls of each sex of the @entity19 combined with 30 vehicle controls of each sex of @entity19 from similar bioassays of two other chemicals. All surviving @entity35 were killed at 81-86 weeks; all surviving @entity19 , at 86 weeks. Mean body weights were @entity308 in @entity35 and @entity19 administered @entity10976 , and mortality was dose related among male and female @entity35 and male @entity19 . The high mortality among the male @entity35 may have been associated with inflammatory lesions observed in the lungs, the liver, and the pleural and peritoneal cavities. Sufficient numbers of female @entity35 and of both male and female @entity19 were at risk for development of late-appearing @entity5 . In the male @entity35 , time-adjusted analysis of the incidence of @entity5 was used for determining statistical significance. In female @entity35 , the incidence of uterine @entity420 was higher in the low- and high-dose groups (P>0.001) than in the pooled controls (controls 0/38, low-dose 10/33, high-dose 11/32); the incidence was also dose related (P<0.001). In male @entity35 , no @entity5 occurred in the dosed groups in a significantly increased incidence. In female @entity19 , the incidence of all @entity1583 ( @entity4812 , @entity1072 , or @entity2214 ), taken together, was higher in the low-dose group (P=0.038) and in the high-dose group (P=0.002) than in the pooled controls (controls 1/45, low-dose 5/31, high-dose 9/34); the incidence was also dose related (P=0.002). In addition, the incidence of these @entity5 in the high-dose group was higher (P=0.026) than that in the vehicle controls (0/15), and the incidence was dose related (P=0.021) using the vehicle controls. In male @entity19 , @entity5 occurred only in two low-dose and two high-dose animals. It is concluded that under the conditions of this bioassay, @entity10976 was carcinogenic for female @entity35 , producing uterine @entity420 , and was also carcinogenic for female B6C3F1 @entity19 , producing @entity706 .

Bioassay of XXXX for possible carcinogenicity.

@entity2214 :: ('MESH:D007945', 'Disease') :: ['lymphocytic leukemias'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depressed'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphomas'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity5 :: ('MESH:D009369', 'Disease') :: ['lymphocytic neoplasms', 'tumors'] @entity4812 :: ('MESH:D016403', 'Disease') :: ['histiocytic lymphomas'] @entity1072 :: ('MESH:D015451', 'Disease') :: ['lymphocytic lymphomas'] @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematopoietic neoplasms'] @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats', 'rats'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas'] @entity10976 :: ('MESH:D011929', 'Chemical') :: ['ICRF-159']
@entity10976 :: (MESH:D011929,Chemical) :: ['ICRF-159']
